US HB7722 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on July 22 2020 - 25% progression, died in committee
Action: 2020-07-22 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on July 22 2020 - 25% progression, died in committee
Action: 2020-07-22 - Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To limit the price of insulin drugs accessible for participants, beneficiaries, and enrollees enrolled in group or individual health insurance coverage and group health plans and for uninsured individuals who have diabetes, and for other purposes.
Title
Matt’s Act
Sponsors
Rep. Jeff Fortenberry [R-NE] | Rep. Angela Craig [D-MN] |
History
Date | Chamber | Action |
---|---|---|
2020-07-22 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-07-22 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2020-07-22 | House | Introduced in House |
Subjects
Business records
Congressional oversight
Digestive and metabolic diseases
Drug therapy
Health
Health care costs and insurance
Health care coverage and access
Inflation and prices
Prescription drugs
Congressional oversight
Digestive and metabolic diseases
Drug therapy
Health
Health care costs and insurance
Health care coverage and access
Inflation and prices
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/7722/all-info |
Text | https://www.congress.gov/116/bills/hr7722/BILLS-116hr7722ih.pdf |